CHMP confirms PRAC Protelos/Osseor restriction
This article was originally published in Scrip
Executive Summary
The EMA's Committee for Medicinal Products for Human Use (CHMP) has confirmed restrictions on the use of Servier's osteoporosis drug Protelos/Osseor (strontium ranelate) because it may increase the risk of heart problems.